Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. US Oncology Research Inc, The Woodlands, TX, United States

Survival: 27.7 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: The Woodlands, TX
Hospital: US Oncology Research Inc
Journal: Link
Date: 1/2010

This phase 2 study involved 60 relapsed or refractory indolent lymphoma patients who were previously treated with rituximab. The median patient age was 70 years and 47% were male.

Patients were treated with the biologic therapy agent called bortezomib, which is classified as a proteasome inhibitor and interferes with cancer cell growth.

The most severe toxicities were of grade 4 and included thrombocytopenia and dehydration. Grade 3 neutropenia, fatigue, and diarrhea were also reported.

The median overall survival was 27.7 months.

This work was partially supported by Millennium Pharmaceuticals Inc.

Correspondence: Dr. Nicholas Di Bella; email:

E-mail to a Friend Email Physician More Information